2. Primary HPV test screening

3. cytology
HPV

14. COBAS
OPTIMA HC

15. COBAS
HPV DNA
OPTIMA
mRNA E6,E7 HC

20. Primary Screening HPV test
increase
reduce
cost
complexity
sensitivity

21. For example:
ATHENA

22. HPV test primary screening
Age 25
28%
Age 30
24%

23. HPV TEST primary screening
NPV: 100%

24. Cytology versus HPV testing for cervical cancer screening in the general population
Cochrane Systematic Review - August 2017

25. Test
Disease threshold
studies
Pooled sensitivity (95% CI)
Pooled specificity (95% CI)
CC (ASCUS+)
CIN 2+ 16
65.87% (54.94 to 75.33)
96.28% (94.72 to 97.39)
LBC (ASCUS+) 15
75.51% (66.57 to 82.68)
91.85% (88.43 to 94.32)
CC (LSIL+) 9
62.84% (46.79‐76.50)
97.73% (96.09‐98.70)
LBC (LSIL+) 10
70.33% (59.73 to 79.11)
96.20% (94.57 to 97.36)
HC2 (1 pg/mL) 25
92.60% (99.45 to 95.30)
89.30% (87.03 to 91.20)
PCR (> 12 types) 6
95.13% (89.50 to 97.84)
91.89% (83.79 to 96.13)
APTIMA 3
92.66% (31.77 to 99.71)
93.31% (47.30 to 99.54)
CIN 3+
70.27% (57.87 to 80.30)
96.67% (94.56 to 98.00) 13
75.97% (64.72 to 84.49)
91.19% (87.21 to 94.01) 5
74.43% (67.81 to 80.10)
96.86% (94.87 to 98.10)
71.91% (51.68 to 86.00)
96.05% (93.53 to 97.60) 19
96.50% (94.00 to 97.90)
89.20% (86.70 to 91.30)

26. International Journal of Cancer
Int J Cancer May 1; 142(9): 1952–1958

27. MIDDLE INCOME COUNTRY 1000,000 women CIN 1: 708 CIN 2:285 CIN 3:436
INVASIVE :85
HPV INCIDENCE: 3.5%
HC 2